171 related articles for article (PubMed ID: 2766587)
1. Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD.
Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK
Clin Nephrol; 1989 Aug; 32(2):96-100. PubMed ID: 2766587
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD.
Macia M; Coronel F; Navarro JF; Gallego E; Herrero JA; Méndez ML; Chahin J; García J
Clin Nephrol; 1997 Sep; 48(3):181-4. PubMed ID: 9342490
[TBL] [Abstract][Full Text] [Related]
4. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
5. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder.
Cheng IK; Lu HB; Chan CY; Cheng SW; Robinson JD; Tam SC; Lo WK; Cheung WC
Clin Nephrol; 1993 Aug; 40(2):100-5. PubMed ID: 8222365
[TBL] [Abstract][Full Text] [Related]
6. CAPD with low calcium dialysate and calcium carbonate: results of a 24-week study.
Honkanen E; Kala AR; Grönhagen-Riska C; Ikäheimo R
Adv Perit Dial; 1992; 8():356-61. PubMed ID: 1361822
[TBL] [Abstract][Full Text] [Related]
7. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
Weinreich T; Ritz E; Passlick-Deetjen J
Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
[TBL] [Abstract][Full Text] [Related]
8. RenaGel efficacy in severe secondary hyperparathyroidism.
Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
10. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
Bro S; Brandi L; Olgaard K
Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
[TBL] [Abstract][Full Text] [Related]
11. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
[TBL] [Abstract][Full Text] [Related]
12. Calcium acetate used as phosphate binding treatment in uremic hyperphosphatemia.
Wikström B; Danielson BG; Fellström B
Adv Perit Dial; 1991; 7():221-4. PubMed ID: 1680430
[TBL] [Abstract][Full Text] [Related]
13. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.
Slatopolsky E; Weerts C; Lopez-Hilker S; Norwood K; Zink M; Windus D; Delmez J
N Engl J Med; 1986 Jul; 315(3):157-61. PubMed ID: 3724805
[TBL] [Abstract][Full Text] [Related]
14. Aluminum concentrations in serum, dialysate, urine and bone among patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Joffe P; Olsen F; Heaf JG; Gammelgaard B; Pödenphant J
Clin Nephrol; 1989 Sep; 32(3):133-8. PubMed ID: 2791364
[TBL] [Abstract][Full Text] [Related]
15. Low calcium peritoneal dialysis solution. Effects on calcium metabolism and bone disease in CAPD patients.
Carozzi S; Nasini MG; Schelotto C; Caviglia PM; Santoni O; Pietrucci A
ASAIO J; 1992; 38(3):M593-5. PubMed ID: 1457929
[TBL] [Abstract][Full Text] [Related]
16. Length of interdialytic interval influences serum calcium and phosphorus concentrations.
Sigrist MK; Devlin L; Taal MW; Fluck RJ; McIntyre CW
Nephrol Dial Transplant; 2005 Aug; 20(8):1643-6. PubMed ID: 15870223
[TBL] [Abstract][Full Text] [Related]
17. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
Kiss D; Battegay M; Meier C; Lyrer A
Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
[TBL] [Abstract][Full Text] [Related]
18. [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options].
Gallar P; Ortega O; Gutiérrez M; Muñoz M; Hilara L; Oliet A; Rodríguez I; Giménez E; Vigil A
Nefrologia; 2000; 20(4):355-61. PubMed ID: 11039261
[TBL] [Abstract][Full Text] [Related]
19. [Replacement of aluminum-containing phosphate binders by calcium and magnesium carbonates in long-term hemodialysis].
Zellweger U; Zaugg PY; Dambacher M; Binswanger U; Gautschi K; Hany A
Dtsch Med Wochenschr; 1989 Apr; 114(17):659-64. PubMed ID: 2707134
[TBL] [Abstract][Full Text] [Related]
20. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
